ETFs CellaVision AB

CEVI

SE0000683484

Advanced Medical Equipment & Technology

Real-time Estimate Cboe Europe 15:31:43 30/09/2026 +04			5-day change	1st Jan Change
174.90 ^SEK	-0.74%		+4.17%	+11.32%

09-28	Better Collective tumbles on weak Stockholm exchange, OMXS30 index down 0.5%	FW
09-28	Stockholm bourse mixed at midday, Better Collective plunges	FW

ETFs positioned on CellaVision AB

Name	YTD change	Weight	AuM
STATE STREET SPDR PORTFOLIO DEVELOPED WORLD EX-US ETF - USD	+13.92%	-.--%	41,780 M€
STATE STREET SPDR S&P INTERNATIONAL SMALL CAP ETF - USD	+11.88%	0.04%	918 M€
DIMENSIONAL INTERNATIONAL SMALL CAP ETF - USD	+10.28%	0.01%	5,871 M€
DIMENSIONAL INTERNATIONAL SUSTAINABILITY CORE 1 ETF - USD	+6.10%	0%	1,193 M€
STATE STREET SPDR PORTFOLIO EUROPE ETF - USD	+4.22%	0%	742 M€
STATE STREET SPDR GLOBAL ALLOCATION ETF - DISTRIBUTING - USD	+6.26%	0%	317 M€
DIMENSIONAL WORLD EQUITY ETF - USD	+12.68%	0%	1,674 M€
DEFINED DURATION 20 ETF - USD	+11.20%	0%	19 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.22%	0%	62 M€
DISCIPLINE FUND ETF - USD	-.--%	0%	73 M€
DEFINED DURATION 5 ETF - USD	-0.34%	0%	18 M€

CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâ€™s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

Employees

251

Sector

Advanced Medical Equipment & Technology

Calendar

10-29 Earnings release - Q3 2026

More about the company